In yet another drug recall, Taro Pharmaceuticals U.S.A. (TARO), Inc. has recalled bipolar disorder and epilepsy drug Lamotrigine due to cross-contamination with Enalapril Maleate – another drug substance used for the treatment of hypertension and congestive heart failure.

The recall affects 100 mg Lamotrigine USP tablets sold in 100-count white plastic bottles with a screw-cap closure. The recalled medication has a lot number of 331771 and an expiration date of June 2021. The NDC number of the drug is 51672-4131-1.

The recalled Lamotrigine was distributed to wholesale distributors in the U.S. from Aug. 23 to Aug. 30, 2019. The contaminated medication was further distributed to retail pharmacies for patient prescriptions. Labels of the recalled medication can be viewed here.

According to the company, the cross-contamination could result in chronic exposure to Enalapril Maleate, which could increase the risk of birth defects in developing fetuses. Taro has not received any reports of adverse reactions from the recalled medication to date.

Consumers that have been prescribed the Lamotrigine tablets should stop using the medication and return it to their pharmacy. A physician or healthcare provider should be contacted if a consumer has any problems related to the affected medication.

Questions about the recall can be directed to Taro at 1-866-923-4914, Monday through Friday from 7 a.m. to 7 p.m. CST or by email at TaroPVUS@taro.com.

Shares of Taro Pharmaceuticals stock were down 0.28% as of 9:43 a.m. EST on Monday.